E-Thesis 533 views
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer / CLAIRE DONNELLY
Swansea University Author: CLAIRE DONNELLY
DOI (Published version): 10.23889/SUthesis.62107
Abstract
Ovarian cancer (OC) has the highest mortality rate of all gynecological cancers, with a low 5-year survival rate. This is in part due to resistance to chemotherapy drugs and recurrence, which causes OC treatments to become inadequate. Exosomes are a type of extracellular vesicle (EV), along with mic...
Published: |
Swansea
2022
|
---|---|
Institution: | Swansea University |
Degree level: | Doctoral |
Degree name: | Ph.D |
Supervisor: | Gonzalez, Deyarina |
URI: | https://cronfa.swan.ac.uk/Record/cronfa62107 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2022-12-02T10:47:29Z |
---|---|
last_indexed |
2023-01-13T19:23:20Z |
id |
cronfa62107 |
recordtype |
RisThesis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2022-12-02T11:17:44.9526677</datestamp><bib-version>v2</bib-version><id>62107</id><entry>2022-12-02</entry><title>Therapeutic Exosomes as Novel Treatment for Ovarian Cancer</title><swanseaauthors><author><sid>5124376ab7d92dbf15f427262e7f2ce5</sid><firstname>CLAIRE</firstname><surname>DONNELLY</surname><name>CLAIRE DONNELLY</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-12-02</date><abstract>Ovarian cancer (OC) has the highest mortality rate of all gynecological cancers, with a low 5-year survival rate. This is in part due to resistance to chemotherapy drugs and recurrence, which causes OC treatments to become inadequate. Exosomes are a type of extracellular vesicle (EV), along with microvesicles and apoptotic bodies. Exosomes act as key mediators of intercellular communication. This leads to the involvement of exosomes in many normal physiological processes including immune responses. However, exosomes derived from tumour cells are implicated in pathological processes, such as cancer progression and metastasis. This study evaluated the role of tumour derived exosomes in OC. This included assessing their biomarker potential. In contrast, non-tumour derived exosomes were evaluated to determine therapeutic ability.</abstract><type>E-Thesis</type><journal/><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher/><placeOfPublication>Swansea</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic/><keywords>Exosomes, Extracellular Vesicles, Ovarian Cancer, Therapeutic, 3D Culture</keywords><publishedDay>26</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-10-26</publishedDate><doi>10.23889/SUthesis.62107</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><supervisor>Gonzalez, Deyarina</supervisor><degreelevel>Doctoral</degreelevel><degreename>Ph.D</degreename><degreesponsorsfunders>HCRW</degreesponsorsfunders><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T11:17:44.9526677</lastEdited><Created>2022-12-02T10:43:46.2267542</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>CLAIRE</firstname><surname>DONNELLY</surname><order>1</order></author></authors><documents><document><filename>Under embargo</filename><originalFilename>Under embargo</originalFilename><uploaded>2022-12-02T11:00:23.7360487</uploaded><type>Output</type><contentLength>12037464</contentLength><contentType>application/pdf</contentType><version>E-Thesis – open access</version><cronfaStatus>true</cronfaStatus><embargoDate>2027-10-26T00:00:00.0000000</embargoDate><documentNotes>Copyright: The author, Claire Ailsa Donnelly, 2022.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807> |
spelling |
2022-12-02T11:17:44.9526677 v2 62107 2022-12-02 Therapeutic Exosomes as Novel Treatment for Ovarian Cancer 5124376ab7d92dbf15f427262e7f2ce5 CLAIRE DONNELLY CLAIRE DONNELLY true false 2022-12-02 Ovarian cancer (OC) has the highest mortality rate of all gynecological cancers, with a low 5-year survival rate. This is in part due to resistance to chemotherapy drugs and recurrence, which causes OC treatments to become inadequate. Exosomes are a type of extracellular vesicle (EV), along with microvesicles and apoptotic bodies. Exosomes act as key mediators of intercellular communication. This leads to the involvement of exosomes in many normal physiological processes including immune responses. However, exosomes derived from tumour cells are implicated in pathological processes, such as cancer progression and metastasis. This study evaluated the role of tumour derived exosomes in OC. This included assessing their biomarker potential. In contrast, non-tumour derived exosomes were evaluated to determine therapeutic ability. E-Thesis Swansea Exosomes, Extracellular Vesicles, Ovarian Cancer, Therapeutic, 3D Culture 26 10 2022 2022-10-26 10.23889/SUthesis.62107 COLLEGE NANME COLLEGE CODE Swansea University Gonzalez, Deyarina Doctoral Ph.D HCRW 2022-12-02T11:17:44.9526677 2022-12-02T10:43:46.2267542 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine CLAIRE DONNELLY 1 Under embargo Under embargo 2022-12-02T11:00:23.7360487 Output 12037464 application/pdf E-Thesis – open access true 2027-10-26T00:00:00.0000000 Copyright: The author, Claire Ailsa Donnelly, 2022. true eng |
title |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer |
spellingShingle |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer CLAIRE DONNELLY |
title_short |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer |
title_full |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer |
title_fullStr |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer |
title_full_unstemmed |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer |
title_sort |
Therapeutic Exosomes as Novel Treatment for Ovarian Cancer |
author_id_str_mv |
5124376ab7d92dbf15f427262e7f2ce5 |
author_id_fullname_str_mv |
5124376ab7d92dbf15f427262e7f2ce5_***_CLAIRE DONNELLY |
author |
CLAIRE DONNELLY |
author2 |
CLAIRE DONNELLY |
format |
E-Thesis |
publishDate |
2022 |
institution |
Swansea University |
doi_str_mv |
10.23889/SUthesis.62107 |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
document_store_str |
0 |
active_str |
0 |
description |
Ovarian cancer (OC) has the highest mortality rate of all gynecological cancers, with a low 5-year survival rate. This is in part due to resistance to chemotherapy drugs and recurrence, which causes OC treatments to become inadequate. Exosomes are a type of extracellular vesicle (EV), along with microvesicles and apoptotic bodies. Exosomes act as key mediators of intercellular communication. This leads to the involvement of exosomes in many normal physiological processes including immune responses. However, exosomes derived from tumour cells are implicated in pathological processes, such as cancer progression and metastasis. This study evaluated the role of tumour derived exosomes in OC. This included assessing their biomarker potential. In contrast, non-tumour derived exosomes were evaluated to determine therapeutic ability. |
published_date |
2022-10-26T04:21:28Z |
_version_ |
1763754417525358592 |
score |
11.030252 |